Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Dateline City:

WHITEHOUSE STATION, N.J.

Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
announced the presentation of interim data from the ongoing C-WORTHY
Study, a Phase II clinical trial evaluating the efficacy and safety of
an all-oral regimen combining once-daily MK-5172, an investigational
hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an
investigational HCV NS5A replication complex inhibitor, with or without
twice-daily ribavirin, administered for 12 weeks to treatment-naïve,
non-cirrhotic pat
Language:

English

Contact:

MerckMedia:Pamela Eisele, [phone]Sarra Herzog, [phone]orInvestor:Carol Ferguson, [phone]Justin Holko, [phone]

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Research and Development News - November 2, 2013 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news